Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGENNASDAQ:EDITNASDAQ:EXOZNYSE:HEXO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$1.45+1.4%$1.40$1.13▼$2.66$129.39M2.61367,848 shs198,521 shsEDITEditas Medicine$1.87+13.3%$1.38$0.91▼$6.22$156.54M2.152.57 million shs2.73 million shsEXOZExozymes$14.00+0.1%$12.06$8.50▼$23.99$117.15MN/A18,691 shs7,350 shsHEXOHEXO$0.71+2.5%$0.87$0.66▼$3.84$31.24M1.35880,508 shs305,500 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen-1.38%+1.42%-3.38%-26.67%-41.39%EDITEditas Medicine+6.45%+0.61%+7.14%-10.33%-70.69%EXOZExozymes-6.11%-7.23%+30.38%-23.13%+1,398,999,900.00%HEXOHEXO0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGENCompugen1.9604 of 5 stars3.54.00.00.02.70.00.0EDITEditas Medicine4.3546 of 5 stars3.14.00.04.23.21.71.3EXOZExozymesN/AN/AN/AN/AN/AN/AN/AN/AHEXOHEXON/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 3.00Buy$4.00175.86% UpsideEDITEditas Medicine 2.29Hold$5.36186.83% UpsideEXOZExozymes 0.00N/AN/AN/AHEXOHEXO 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HEXO, EDIT, EXOZ, and CGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.004/29/2025EDITEditas MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$27.59M4.69N/AN/A$0.73 per share1.99EDITEditas Medicine$35.84M4.37N/AN/A$4.27 per share0.44EXOZExozymesN/AN/AN/AN/AN/AN/AHEXOHEXO$146.20M0.21N/AN/A$2.44 per share0.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen-$18.75M-$0.1672.50N/AN/A2.67%2.62%1.36%8/5/2025 (Estimated)EDITEditas Medicine-$153.22M-$3.04N/AN/AN/A-340.96%-80.13%-50.99%8/6/2025 (Estimated)EXOZExozymesN/AN/A0.00∞N/AN/AN/AN/AN/AHEXOHEXO-$845.90M-$5.21N/AN/AN/A-235.33%-74.04%-32.51%N/ALatest HEXO, EDIT, EXOZ, and CGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025CGENCompugen-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million5/12/2025Q1 2025EXOZExozymesN/A-$0.22N/A-$0.22N/AN/A3/5/2025Q4 2024EDITEditas Medicine-$0.39-$0.55-$0.16-$0.55$37.17 million$30.60 million3/4/2025Q4 2024CGENCompugen$0.07-$0.07-$0.14-$0.07$17.47 million$1.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AEXOZExozymesN/AN/AN/AN/AN/AHEXOHEXON/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A4.144.14EDITEditas MedicineN/A3.753.75EXOZExozymesN/AN/AN/AHEXOHEXO0.010.410.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%EDITEditas Medicine71.90%EXOZExozymesN/AHEXOHEXO7.78%Insider OwnershipCompanyInsider OwnershipCGENCompugen9.50%EDITEditas Medicine1.90%EXOZExozymesN/AHEXOHEXO4.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7089.24 million80.76 millionOptionableEDITEditas Medicine23083.71 million80.98 millionOptionableEXOZExozymes298.37 millionN/AN/AHEXOHEXO1,27744.00 million41.93 millionOptionableHEXO, EDIT, EXOZ, and CGEN HeadlinesRecent News About These CompaniesExpert reveals most dangerous garden accessories to watch out for as Britain heats up – causing fires & electric shocksApril 10, 2025 | thesun.ieTilray wins dismissal of $8M shareholder lawsuitMarch 26, 2025 | greenmarketreport.comNEXTG3N series from ARI: Cutting-edge butterfly valves delivering efficiency, durability and customizationNovember 6, 2024 | insights.globalspec.comHexo co-founder Adam Miron launches new advisory firm with former business partnerOctober 29, 2024 | obj.caWarning issued to anyone who uses a heated clothes airer in their homeOctober 24, 2024 | msn.comSCREEN magazine to be unveiled today: Shraddha Kapoor, Rajkumar Hirani and Vijay Varma to lead star-studded relaunchOctober 18, 2024 | financialexpress.comIconic SCREEN magazine to be unveiled today, Shraddha Kapoor to be its first-ever digital coverOctober 18, 2024 | indianexpress.comShraddha Kapoor to unveil SCREEN; will be face of its first digital coverOctober 18, 2024 | indianexpress.comDo you need a cover for your heated airer? It’ll definitely speed up drying - but only if you choose the right kindOctober 12, 2024 | idealhome.co.ukPrevisão de ações da Tilray Brands: níveis a serem observados antes dos lucrosOctober 8, 2024 | msn.comTilray Brands stock forecast: levels to watch ahead of earningsOctober 7, 2024 | invezz.comThe 8 most common fire risks in your home – and how to prevent themOctober 2, 2024 | msn.comA 614-Square-Foot Art Nouveau Apartment in France Gets a Bold UpdateSeptember 30, 2024 | architecturaldigest.comElectric blanket users must do these five things as temperatures plummetSeptember 29, 2024 | express.co.ukTech30: most promising Indian startups of 2024September 27, 2024 | yourstory.comMedical Marijuana Market to Grow by USD 39.8 Billion (2024-2028), Driven by Product Launches, How AI is Shaping the Market - Technavio ReportSeptember 9, 2024 | finance.yahoo.comIs Hexo Corp (HEXO) Stock a Good Investment?September 4, 2024 | aaii.comTwo cannabis stocks analysts love right nowAugust 28, 2024 | cantechletter.comVillage Farms is “incredibly undervalued”, Beacon saysAugust 21, 2024 | cantechletter.comTilray to Acquire Craft Beer Brands from Molson CoorsAugust 13, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongAlphabet Stock Lags—But Waymo May Be Its Hidden DriverBy Gabriel Osorio-Mazilli | May 25, 2025View Alphabet Stock Lags—But Waymo May Be Its Hidden DriverArcher Posts Surprise Q1 Beat, Sets Stage for 2025 Revenue LaunchBy Jeffrey Neal Johnson | May 14, 2025View Archer Posts Surprise Q1 Beat, Sets Stage for 2025 Revenue LaunchCRSPR Stock Could Be Ready to Deliver on Its Massive PromiseBy Chris Markoch | May 16, 2025View CRSPR Stock Could Be Ready to Deliver on Its Massive PromiseHEXO, EDIT, EXOZ, and CGEN Company DescriptionsCompugen NASDAQ:CGEN$1.45 +0.02 (+1.40%) Closing price 04:00 PM EasternExtended Trading$1.46 +0.01 (+0.34%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Editas Medicine NASDAQ:EDIT$1.87 +0.22 (+13.33%) Closing price 04:00 PM EasternExtended Trading$1.86 -0.01 (-0.53%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Exozymes NASDAQ:EXOZ$14.00 +0.01 (+0.07%) As of 01:10 PM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.HEXO NYSE:HEXOHEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
